Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis
Status:
Completed
Trial end date:
2019-11-25
Target enrollment:
Participant gender:
Summary
Children with Cystic Fibrosis, ages greater than and equal to 36 months of age and less than
or equal to 18 years of age, with a 25OHD level less than 30 ng/dL will be asked to
participate in this study. Upon consent, they will be given oral cholecalciferol
supplementation of 250,000 IU during their next CF clinic visit. The safety will be assessed
by measuring a serum calcium level within 1 week of supplementation. Efficacy will be
assessed using repeated 25OHD levels throughout the course of 12 months. Feasibility will be
assessed with the previous two measures as well as a brief questionnaire administered via
telephone within 1 week of supplementation.